In June 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for famotidine-containing medicines to include warnings about potential drug interactions with posaconazole and certain tyrosine kinase inhibitors. (ema.europa.eu) This highlights the importance of continuous monitoring and updating of safety information for established drugs.
In September 2023, the NPPA revised the ceiling price for famotidine tablets in India, reflecting adjustments to ensure the drug remains affordable while considering manufacturing costs and market dynamics. This demonstrates the Indian government's commitment to balancing affordability with industry sustainability.
In November 2023, the FDA issued a guidance document outlining new requirements for the stability testing of famotidine formulations, aiming to enhance product quality and shelf-life standards. This move underscores the FDA's focus on ensuring the long-term efficacy and safety of pharmaceutical products.
In January 2024, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of famotidine, which reflects its continued relevance in treating acid-related disorders globally.
In March 2024, the CDSCO implemented stricter regulations for the export of pharmaceutical products, including famotidine, requiring additional quality certifications to enhance the credibility of Indian exports in international markets. This initiative aims to bolster the reputation of Indian pharmaceuticals and ensure compliance with global quality standards.
